Stocks · News reference
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100 billion-$3.200
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.
Amneal Pharmaceuticals shares surged 8.6% following completion of its Kashiv BioSciences acquisition, creating an integrated biosimilars platform. However, consensus EPS estimates were revised 23.1% lower over the past month, which could limit future gains. Ionis Pharmaceuticals declined 5.1% with unchanged negative EPS expectations.
Wall Street analysts made mixed price-target changes for LYFT, AMRX, JBHT, CRM, APPF, FLNC and CRWD.
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.